K
Korro Bio, Inc. (KRRO)
NCM – Real Time Price. Currency in USD
10.40
-0.51 (-4.67%)
At close: Mar 27, 2026, 4:00 PM EDT
10.40
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:10 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
10.40
-0.51 (-4.67%)
At close: Mar 27, 2026, 4:00 PM EDT
10.40
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:10 PM EDT
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company’s lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
| Name | Position |
|---|---|
| Dr. Andrew Fraley Ph.D. | Co-Founder & Advisor |
| Dr. Gaozhong Zhu Ph.D. | SVP of Chemistry, Manufacturing and Controls & Technical Operations |
| Dr. Joshua Rosenthal Ph.D. | Co-Founder & Advisor |
| Dr. Loic Vincent Ph.D. | Chief Scientific Officer |
| Mr. Jeffrey M. Cerio J.D., Pharm.D. | Senior VP, General Counsel & Corporate Secretary |
| Mr. Oliver Dolan | Senior VP of Finance & Principal Accounting Officer |
| Mr. Todd Chappell M.B.A. | Chief Operating Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-13 | S-3 | d42330ds3.htm |
| 2026-03-12 | 10-K | krro-20251231.htm |
| 2026-03-09 | 8-K | krro-20260309.htm |
| 2026-01-27 | S-8 | krro-20260127.htm |
| 2026-01-15 | 8-K | krro-20260115.htm |
| 2025-12-18 | 8-K | krro-20251215.htm |
| 2025-11-12 | 8-K | krro-20251107.htm |
| 2025-10-08 | 8-K | krro-20251007.htm |
| 2025-08-12 | 10-Q | krro-20250630.htm |
| 2025-06-18 | 8-K/A | krro-20250611.htm |
| Ms. Stephanie Engels |
| Chief People Officer |